康莱特注射液联合放化疗治疗恶性肿瘤的临床研究  

Clinical studies in combination of Kanglaite injection and radiotherapy/chemotherapy in the treatment of malignancies.

作　　者：梁荣祥[1] 宋玉琴[1] 颜廷秀[1] 李冠桢[1] 杨哲[1] 王兴文[1] 王瑜[1] 

机构地区：[1]山东省立医院,山东济南250021

出　　处：《陕西肿瘤医学》2002年第4期305-306,共2页ShanXi Oncology Medicine

摘　　要：目的　探讨康莱特注射液联合放、化疗对恶性肿瘤的治疗效果。方法　符合入选标准的患者共 2 19例 ,随机分为治疗组 (康莱特 +放 化疗综合治疗组 )和对照组 (单纯放或化疗组 ) ,观察标准包括 :肿瘤客观疗效 (肿瘤大小 )、症状及体重、生活质量改变、免疫功能及外周血象变化、副作用等。结果　康莱特注射液联合放化疗能在一定程度上提高恶性肿瘤的治疗疗效 ,改善症状 ,增加体重 ,使生活质量得到提高 ,同时还能有效保护骨髓 ,防止放化疗期间血象下降 ,显著提高机体免疫功能。而该药对心、肝、肾等脏器无明显毒副作用。结论　康莱特注射液是一种安全、有效、双相广谱抗癌药物 。Objective To investigate the effectiveness of Kanglaite injection combining with radiotherapy/chemotherapy in the treatment of malignancies.Methods Two hundred and nineteen patients with malignancies were selected and divided into two groups randomly:treatment group (Kanglaite injection+ratiotherapy/chemotherapy) and control group(radiotherapy/chemotherapy only). The observing indicators included:size of tumor, symptoms, boby weight, life quality, immune function, count of peripheral blood cells, side effects and so on.Results Kanglaite injection combining with radiotherapy/chemotherapy could improve the treatment effectiveness of malignancies, reduce symptoms, increase body weight and immune function significantly. It could also protect bone marrow in radiotherapy/chemotherapy. No evident side effect to heart, liver and kidneys was found.Conclusion Kanglaite injection is a safe, effective, double-phase and wide-spectrum anticancer drug, can be used in the first-line therapy of malignancies.

关 键 词：康莱特注射液 化疗 恶性肿瘤 临床研究 放射治疗 中西医结合 

分 类 号：R730.58[医药卫生—肿瘤]